Novo Nordisk partnered with OpenAI for AI in drug discovery and operations, and is rolling out oral Wegovy globally after US launch. EU regulators recommended approval of Wegovy 7.2 mg and oral semaglutide, showing strong weight loss efficacy. However, Eli Lilly's retatrutide set a new weight-loss benchmark, intensifying competition. Patent issues in Canada also emerged.